# Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

> **NCT01793610** · PHASE2 · COMPLETED · sponsor: **Resilient Pharmaceuticals** · enrollment: 29 (actual)

## Conditions studied

- Posttraumatic Stress Disorder

## Interventions

- **DRUG:** Comparator Dose (40mg) MDMA HCl
- **DRUG:** Active Dose 2 (100 mg) MDMA HCl
- **DRUG:** Active Dose 1 (125 mg) MDMA HCl
- **BEHAVIORAL:** Psychotherapy

## Key facts

- **NCT ID:** NCT01793610
- **Lead sponsor:** Resilient Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-13
- **Primary completion:** 2015-12-03
- **Final completion:** 2017-02-01
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01793610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01793610, "Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01793610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*